September 8, 2011
The company said Dr. David J. Drutz has been elected chairman, and entrepreneur and accountant Tim Gupton has joined the board.
June 30, 2011
The drug giant recently purchased Raleigh-based Inspire Pharmaceuticals. In a notice filed with the state, the expected closure of Inspire's offices is made official.
May 17, 2011
Some company executives will be leaving the eye drug firm as it is absorbed by the pharmaceutical giant.
Updated May 10, 2011
The Raleigh-based pharmaceutical firm, which is in the process of being acquired by drug giant Merck, says losses increased nearly $3 million from a year ago.
Updated April 6, 2011
Merck will pay $5 a share for Inspire. Both boards and a major Inspire investor have already approved the deal. Inspire's shares collapsed in January after a failed drug trial.
March 18, 2011
Inspire offers bonuses; Dex One seeks feedback on executive pay; Lowes to sell Nexxus LED lighting; NC toll roll RFID devices clear tests.
February 17, 2011
Inspire Pharmaceuticals said Thursday that it is laying off 65 people, or 27 percent of its work force related to the drug's development.
January 4, 2011
Shares in the Raleigh-based pharmaceutical firm plunged Monday on news of a failure for its drug targeting cystic fibrosis.
Updated January 3, 2011
The company, which just moved to Raleigh, says its candidate for treatment of cystic fibrosis fails to meet efficacy goals in Phase III clinical trial.
December 13, 2010
The Durham-based pharmaceutical firm's partner in Japan receives approval to launch Diquas. That news triggers a milestone payment plus future royalties.
Updated November 4, 2010
The Durham-based pharmaceutical firm loses far less than forecast - 9 cents per share rather than 14 cents as expected.
Updated August 25, 2010
The Durham-based firm regains control of failed drug candidate Prolacria. Inspire also will receive smaller royalties from Allegran for sales of eye drug Restasis.
May 3, 2010
Durham-based pharmaceutical firm reduces losses by $4.6 million from a year ago as eye drug sales surge.
Updated March 15, 2010
Shares at pharmaceutical firm stage a comeback from a 13 percent drop at the open. Inspire says it will continue researching possible use of its pink eye drug AzaSite to treat another eye condition.
March 4, 2010
Durham-based pharmaceutical firm reports a lower than expected quarterly loss.
February 24, 2010
Adrian Adams receives 25% of the options immediately, including nearly 90,000 at $6.35 per share which was the closing price on his first day as the new boss. He replaced Christy Shaffer as of Monday.